US Markets
Home›US Markets›Sectors›Pfizer, Nvidia and others highlighted as long-term div…
Pfizer, Nvidia and others highlighted as long-term dividend stock picks
The article points to Pfizer's 6.9% forward dividend yield and its plans to add at least eight blockbuster drugs by 2030, supported by acquisitions and in-house development.
Housing and lifestyle investing content is driving a new dividend-stock roundup from The Motley Fool, which highlights three companies positioned as long-term income holdings.
The piece says Pfizer has a forward-looking dividend yield of 6.9% and argues the company is building new profit engines, citing its 2023 acquisition of Seagen and Seagen oncology pipeline assets such as Padcev, including a recently approved use for muscle-invasive bladder cancer in combination with Merck's Keytruda.
The article also describes Pfizer's expected path to grow drug revenues, saying it aims to bring at least eight new blockbuster drugs to market by 2030, funded through a mix of acquisitions and internal development.
Beyond oncology, the author flags Pfizer's push into obesity treatment, pointing to its late-2025 acquisition of Metsera and Metsera's MET-097i GLP-1 approach, which it says is showing efficacy with a monthly dose.